EC:, GIG27, Glutamate carboxypeptidase II, NAALADase I, FOLH, Cell growth-inhibiting gene 27 protein, PSM, N-acetylated-alpha-linked acidic dipeptidase I, GCPII, Folylpoly-gamma-glutamate carboxypeptidase, Folate hydrolase 1, FOLH1, Pteroylpoly-Gamma-Glutamate Carboxypeptidase, Membrane Glutamate Carboxypeptidase, Glutamate Carboxypeptidase 2, Glutamate Carboxylase II, NAALAD1, FGCP, PSMA, MGCP, Folate Hydrolase (Prostate-Specific Membrane Antigen) 1, N-Acetylated Alpha-Linked Acidic Dipeptidase 1, Prostate Specific Membrane Antigen Variant F, Prostate-Specific Membrane Antigen, EC, NAALAdase, GCP2

KO Status

F1 (+/-)

Drug Information

Launched drugs: 2
Drugs in clinical trials: 20
Latest Research Phase: Approved

Drug Name





Clinical Trials

Gallium GA-68 PSMA-11

Ga-68-PSMA-11, Ga-68-PSMA



Prostatic Neoplasms

Capromab pendetide

lndium-CYT-356, Indium-111-CYT-356, CYT-356, 111In CYT-356


Eusa Pharma

Prostatic Neoplasms


Phase 3 Clinical

Johns Hopkins University

Carcinoma, Renal Cell, Prostatic Neoplasms


INO5401, INO-5401

Phase 2 Clinical


Glioblastoma, Carcinoma, Transitional Cell


Zr89-J591, 89Zr-DFO-J591, 89Zr-DFO-huJ591

Phase 2 Clinical

Memorial Sloan Kettering Cancer Center

Prostatic Neoplasms


1095, [131I]MIP-1095, [131I]MIP-1466

Phase 2 Clinical

Progenics Pharmaceuticals Inc

Prostatic Neoplasms


J-591, MLN-591, huJ-591, muJ-591, 90Y-J591, MLN-591RL, 177Lu-J591, Lu-177-J591

Phase 2 Clinical

Cornell University

Prostatic Neoplasms

4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute)

Phase 2 Clinical

Shenzhen Geno-Immune Medical Institute



177Lu-PSMA-R2, 177Lu-PSMA-SR6

Phase 2 Clinical

Advanced Accelerator Applications

Prostatic Neoplasms



Phase 2 Clinical

Harpoon Therapeutics

Prostatic Neoplasms





Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen

Israeli R.S., Powell C.T., Fair W.R., Heston W.D.W.,

Cancer Res. 53:227-230(1993)

Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression

Su S.L., Huang I.-P., Fair W.R., Powell C.T., Heston W.D.W.,

Cancer Res. 55:1441-1443(1995)

Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II

Luthi-Carter R., Barczak A.K., Speno H.D., Coyle J.T.,

Brain Res. 795:341-348(1998)

Structure of membrane glutamate carboxypeptidase

Rawlings N.D., Barrett A.J.,

Biochim. Biophys. Acta 1339:247-252(1997)

Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II

Speno H.S., Luthi-Carter R., Macias W.L., Valentine S.L., Joshi A.R.T., Coyle J.T.,

Mol. Pharmacol. 55:179-185(1999)

Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry

Zhang H., Li X.-J., Martin D.B., Aebersold R.,

Nat. Biotechnol. 21:660-666(2003)

Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity

Barinka C., Sacha P., Sklenar J., Man P., Bezouska K., Slusher B.S., Konvalinka J.,

Protein Sci. 13:1627-1635(2004)

Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene

O'Keefe D.S., Bacich D.J., Heston W.D.W.,

Prostate 58:200-210(2004)

Expression of prostate-specific membrane antigen in normal and malignant human tissues

Kinoshita Y., Kuratsukuri K., Landas S., Imaida K., Rovito P.M. Jr., Wang C.Y., Haas G.P.,

World J. Surg. 30:628-636(2006)

Expression of glutamate carboxypeptidase II in human brain

Sacha P., Zamecnik J., Barinka C., Hlouchova K., Vicha A., Mlcochova P., Hilgert I., Eckschlager T., Konvalinka J.,

Neuroscience 144:1361-1372(2007)